Figure 2From: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trialAdjusted mean changes from baseline HbA 1c over 76 weeks (repeated-measures analysis). Randomized and treated patients. Patients who received placebo in the short-term period were switched to blinded metformin 500 mg at week 24. Titration of blinded metformin was not allowed. BL: baseline; HbA1c: glycated hemoglobin; PBO: placebo; SAXA: saxagliptin.Back to article page